These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 26423618

  • 1. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
    Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA.
    Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I.
    BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P.
    BMC Cancer; 2013 Aug 14; 13():386. PubMed ID: 23945072
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW, Lee BH, Jeon MJ, Yu ES, Kim DS, Lee SR, Sung HJ, Choi CW, Park Y, Kim BS.
    Cancer Med; 2020 Sep 14; 9(17):6102-6110. PubMed ID: 32633471
    [Abstract] [Full Text] [Related]

  • 5. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 6. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, Avisar N.
    Oncologist; 2016 Jan 01; 21(1):7-15. PubMed ID: 26668251
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.
    Ann Oncol; 2002 Jun 01; 13(6):903-9. PubMed ID: 12123336
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
    Zhang W, Jiang Z, Wang L, Li C, Xia J.
    Med Oncol; 2015 May 01; 32(5):147. PubMed ID: 25820754
    [Abstract] [Full Text] [Related]

  • 11. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH.
    Support Care Cancer; 2017 Feb 01; 25(2):505-511. PubMed ID: 27709313
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R.
    Support Care Cancer; 2016 Jan 01; 24(1):395-400. PubMed ID: 26092233
    [Abstract] [Full Text] [Related]

  • 17. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.
    Invest New Drugs; 2013 Oct 01; 31(5):1300-6. PubMed ID: 23677653
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 01; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 20. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep 01; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.